Results 121 to 130 of about 20,698 (251)

Hormonal Contraception and Initiation of Semaglutide Therapy

open access: yes
Importance Concerns regarding weight changes during hormonal contraceptive use may influence health care–seeking behavior and contraceptive use patterns.
Hannah Karin Wood-Kurland   +6 more
core   +1 more source

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source

Amylin analogues as a novel perspective in anti‐obesity therapy

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Public health systems face a major challenge because of the worldwide obesity epidemic. The number of obese individuals has increased dramatically and, even in Switzerland which may be considered a relatively “lean” country, the numbers are alarmingly high and have reached almost 50% of the adult population.
Thomas A. Lutz
wiley   +1 more source

Gut microbiota as a novel therapeutic target for eating disorders and obesity

open access: yesBritish Journal of Pharmacology, EarlyView.
The graphical abstract highlights the bidirectional interaction between the gut microbiota and central homeostatic and hedonic mechanisms regulating food intake, which contributes to overweight and obesity. It also illustrates emerging microbiota‐based biomarkers and therapeutic strategies (including prebiotics, probiotics, postbiotics, synbiotics and ...
Solveiga Samulėnaitė   +5 more
wiley   +1 more source

Peripheral targets for neuropathic pain

open access: yesBritish Journal of Pharmacology, EarlyView.
Neuropathic pain represents a significant clinical challenge, with still limited pharmacological approaches to symptomatic relief. This review focuses on molecular targets implicated in neuropathic pain, particularly those involved in peripheral mechanisms. Using the IUPHAR/BPS database of biological targets, their occurrence together with ‘neuropathic
Amirhossein Afsharipour   +3 more
wiley   +1 more source

The glucagon-like peptide-1 receptor-agonist semaglutide

open access: yes, 2019
Semaglutide is a glucagon-like peptide-1 receptor-agonist (GLP-1 RA), which is injected subcutaneously once a week for treatment of Type 2 diabetes. In this review, the present results of semaglutide treatment are presented.
Juhl, Christian Rimer   +3 more
core   +1 more source

7947 Semaglutide Induced Pancreatitis: A Case Report

open access: yes
Disclosure: T. Altaweel: None. A. Mathew: None. P. Chalasani: None. L. Lawrence: None. S. Hussain: None. N. Aldaoud: None. Introduction/Background: As semaglutide (GLP1 RA) has become a cornerstone in diabetes and weight management, there have been ...
Altaweel, Tamara   +6 more
core   +1 more source

Re‐thinking peripheral dysfunctions in obesity: The emerging role of sulphaceutics and sulphanutraceutics

open access: yesBritish Journal of Pharmacology, EarlyView.
Obesity is a chronic, relapsing, multisystem disease in which cardiometabolic risk arises from excess adiposity and progressive dysfunction of peripheral organs, ultimately disrupting endocrine and metabolic crosstalk among tissues. Within this network, sulphur‐based biology, centred on hydrogen sulphide and related reactive sulphur species, has ...
Martina Smimmo   +4 more
wiley   +1 more source

Therapeutic access points: The roles of circumventricular organs in drug delivery and metabolic regulation

open access: yesBritish Journal of Pharmacology, EarlyView.
The current obesity drug landscape, dominated by GLP‐1 receptor agonists and emerging multi‐agonist therapies, has reinforced that long‐term weight loss is achieved in large part through central mechanisms that suppress appetite and reshape energy balance.
Ines Martinez‐Corral   +3 more
wiley   +1 more source

Semaglutide Effects on Metabolic Outcomes in Diabetes Mellitus Patients — Real World Study

open access: yes
Carlos Mario Balcázar-Valencia,1 Andrés Felipe García-Ramos,2– 5 Luis Miguel Osorio-Toro,2,3,6 Yessica Alejandra Ordoñez-Guzmán,3 Nathalia Buitrago-Gómez,4 William Fernando Cabarcas-López,7 Carlos Javier Vizcaino-Guerrero,8 Jorge Enrique Daza-Arana,2,9 ...
Ramírez-Rincón A   +9 more
core  

Home - About - Disclaimer - Privacy